The Mayo Alzheimer's Disease Research Center (ADRC) operates in Rochester, MN, and Jacksonville, FL, recruiting and following subjects for the purpose of pursuing the primary themes of the center. The Clinical Core of the ADRC is the focal point of activity of the Center and will recruit and characterize subjects for all three research projects.
The specific aims of the Core are 1) to recruit and follow subjects on the AD degenerative spectrum with a particular focus on early disease (MCI), 2) to recruit African-American subjects on the AD degenerative spectrum with special focus on early disease (MCI), 3) to recruit and follow subjects with non-AD dementia, e.g., frontotemporal dementia, dementia with Lewy bodies, corticobasal degeneration, 4) to obtain and analyze MRI studies on selected groups of subjects, e.g., normaI-MCI-AD subjects, and provide frontotemporal dementia subjects for Project 1, and 5) to supply subjects for the Neuropathology Core and Projects 1, 2 and 3 of the ADRC. In Rochester, cognitively-impaired (CI) and normal control (NC) subjects will be derived from community and regional resources. In Jacksonville, the CI and NC African-American subjects, as well as indigent CI subjects, will be derived from community resources. The NC and CI subjects will be evaluated and followed in an identical fashion between the two sites, and all of the data will be entered into a common database. The subjects will be screened for participation in Projects 1, 2, and 3 as well as several other ongoing and future studies. The concerns and suggestions from the summary statement for the prior ADRC grant application and from the External Advisory Committee have been addressed. Most of the activities will be a continuation of current practices in the Mayo ADRC, with emphases on the primary themes of the center: the clinical, genetic, neuropsychological, neuroradiologic, and neuropathologic characterization of Caucasian and African-American subjects with normal cognition, mild cognitive impairment, and Alzheimer's disease of mild to moderate severity, and the characterization of subjects with non-AD dementias.
| Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872 |
| Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064 |
| Jack Jr, Clifford R; Wiste, Heather J; Schwarz, Christopher G et al. (2018) Longitudinal tau PET in ageing and Alzheimer's disease. Brain 141:1517-1528 |
| Jung, Youngsin; Jordan 3rd, Lennon G; Lowe, Val J et al. (2018) Clinicopathological and 123I-FP-CIT SPECT correlations in patients with dementia. Ann Clin Transl Neurol 5:376-381 |
| Townley, Ryan A; Botha, Hugo; Graff-Radford, Jonathan et al. (2018) 18F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. Neuroimage Clin 18:897-902 |
| Kidana, Kiwami; Tatebe, Takuya; Ito, Kaori et al. (2018) Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice. EMBO Mol Med 10: |
| Li, Zeran; Del-Aguila, Jorge L; Dube, Umber et al. (2018) Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Med 10:43 |
| Arnold Fiebelkorn, Catherine; Vemuri, Prashanthi; Rabinstein, Alejandro A et al. (2018) Frequency of Acute and Subacute Infarcts in a Population-Based Study. Mayo Clin Proc 93:300-306 |
| Baker, Darren J; Petersen, Ronald C (2018) Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest 128:1208-1216 |
| Ramsey, Christine M; Gnjidic, Danijela; Agogo, George O et al. (2018) Longitudinal patterns of potentially inappropriate medication use following incident dementia diagnosis. Alzheimers Dement (N Y) 4:1-10 |
Showing the most recent 10 out of 1014 publications
